Innova Captab (INNOVACAP) Fundamentals 2026 — P/E 39.6x, Revenue Analysis | SniperIQ
Innova Captab (INNOVACAP) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹5,574 Crore, trading at ₹974.10 on the NSE. This SniperIQ fundamentals page covers Innova Captab's valuation (P/E 39.6x, P/B 5.1x), profitability (net margin 8.6%), revenue (₹1,604 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Innova Captab's market cap?
Innova Captab (INNOVACAP) has a market capitalization of approximately ₹5,574 Crore, trading at ₹974.10 on the NSE. Market cap moves with the live share price.
What is Innova Captab's P/E ratio?
Innova Captab's trailing twelve-month P/E ratio is 39.6x, with a price-to-book (P/B) of 5.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Innova Captab?
Innova Captab runs a net profit margin of 8.6%, a gross margin of 25.5%, and an operating margin of 11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Innova Captab generate?
Innova Captab reported revenue of ₹1,604 Crore for fiscal year 2026, with net income of ₹141 Crore and earnings per share (EPS) of 24.63. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Innova Captab pay a dividend?
Innova Captab offers a trailing dividend yield of about 0.2%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Innova Captab financially healthy?
Innova Captab carries a debt-to-equity ratio of 0.32x and a current ratio of 1.87x, with a market beta of -0.05. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Innova Captab a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Innova Captab (INNOVACAP) the key facts are: market cap ₹5,574 Crore, P/E 39.6x, revenue ₹1,604 Crore, 52-week range 622-1034.85. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Innova Captab's full fundamentals live
Get Innova Captab's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.